Compare BlackBerry Limited (BB) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BlackBerry Limited vs Viatris Inc — how do they compare? BlackBerry Limited trades at $8.85 (market cap $5.27B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 3.5× BlackBerry Limited's market cap, and Viatris Inc pays a 2.95% dividend while BlackBerry Limited pays none. Which is the better fit depends on your goals.
| BB | VTRS | |
|---|---|---|
Market Cap | $5.27B | $18.69B |
Sector | Technology | Health |
52-Week High | $12.81 | $17.86 |
52-Week Low | $3.15 | $9.49 |
Enterprise Value | $5.14B | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BlackBerry (BB) trades at $8.87, up 0.45% in the last session, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beats, including Q1 2026 EPS of $0.06 versus $0.05 expected, highlight operational momentum. Revenue for 2025 was $534.90M, with a net loss of -$79M, though 2026 guidance projects a return to profitability. Positive cash flow from operations of $16.50M in 2025 marks an improvement from prior years.
The stock offers speculative upside driven by QNX and secure communications growth, with a consensus price target of $10.50. However, high valuation ratios like a P/E of 89.8 and execution risks temper optimism. Investor sentiment is mixed, with most analysts rating Hold, citing premium valuation concerns amid a competitive landscape.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BlackBerry Limited
BlackBerry Limited provides intelligent security software solutions. The Company offers artificial intelligence and machine learning for cybersecurity, safety, and data privacy solutions, as well as endpoint security and management, encryption, and embedded systems. BlackBerry serves governments and enterprise sectors worldwide.
Read more on BB →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
